REG - OptiBiotix Health - Director/PDMR Shareholding

OptiBiotix HealthAnnouncement

25/03/2022 14:45

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220325:nRSY1109Ga&default-theme=true

RNS Number : 1109G  OptiBiotix Health PLC  25 March 2022

OptiBiotix Health plc

("OptiBiotix" or the "Company")

 

PDMR Dealings

 

OptiBiotix Health plc (AIM:
OPTI), a life sciences business developing compounds to tackle obesity, high
cholesterol, blood pressure and diabetes, announces that it was notified
today of the following share purchases made by René Kamminga, CEO of
Optibiotix Ltd:

 

 Date of transaction  Number of shares purchased  Price
 23 March 2022        10,000                      40p
 24 March 2022        2,656                       38p

 

 

Following the above transactions, Mr Kamminga is interested in 55,844 ordinary
shares in the Company, representing 0.06 per cent. of the Company's issued
share capital.

 

This announcement contains information which, prior to its disclosure, was
considered inside information for the purposes of the UK Market Abuse
Regulation and the Directors of the Company are responsible for the release of
this announcement.

 

For further information, please contact:

 

 OptiBiotix Health plc                                     www.optibiotix.com (http://www.optibiotix.com/)
 Stephen O'Hara, Chief Executive  Contact via Walbrook below

 Cairn Financial Advisers LLP (NOMAD)                      Tel: 020 7213 0880
 Liam Murray / Jo Turner / Ludovico Lazzaretti

 Cenkos Securities plc (Broker)                            Tel: 020 7397 8900
 Callum Davidson / Neil McDonald
 Michael Johnson / Russell Kerr (Sales)

 Walbrook PR Ltd                                           Mob: 07876 741 001
 Anna Dunphy

 

 

 Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No.
 596/2014
 1   Details of the person discharging managerial responsibilities/person closely
     associated
 a.  Name                                                         René Kamminga
 2   Reason for notification
 a.  Position/Status                                              PDMR
 b.  Initial notification/                                        Initial Notification

     Amendment
 3   Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a.  Name                                                         OptiBiotix Health Plc
 b.  LEI                                                          213800UKYQFT941QHS14
 4   Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a.  Description of the financial instrument, type of instrument  Ordinary shares of 2p each

Identification Code

                                                                  ISIN: GB00BP0RTP38
 b.  Nature of the transaction                                    Purchase of 12,656 ordinary shares in the Company

 c.  Price(s) and volume(s)
                                                                               Price(s) per share  Volume(s)
     40p                                                                       10,000

     38p                                                                       2,656

 d.  Aggregated information

     -       Volume                                               12,656

     -       Price                                                Average price of 39.6p
 e.  Date of the transaction                                      23 and 24s March 2022
 f.  Place of the transaction                                     London Stock Exchange, AIM

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHSELFLIEESEDD